Recent investigations of histone deacetylase inhibitors in renal cell carcinoma

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 4, 2009, Pages 252-254

  Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; BEVACIZUMAB; EVEROLIMUS; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; ISOTRETINOIN; LDH 589; MAMMALIAN TARGET OF RAPAMYCIN; RETINOIC ACID RECEPTOR BETA; SNDX 275; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL SURVIVAL; CHROMATIN; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; NONHUMAN; PROTEIN DEGRADATION; REGULATORY T LYMPHOCYTE; SKIN LYMPHOMA; T CELL LYMPHOMA; UNITED STATES;

ACETYLATION; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; KIDNEY NEOPLASMS;

EID: 66349097613     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Anticancer activities of histone deacetylase inhibitors. Bolden JE, Peart MJ, Johnstone RW. Nat Rev Drug Discov. 2006 Sep;5(9):769-84
2. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584. Cancer Res. 2004 Sep 15;64(18):6626-34
3. Wang XF, Qian DZ, Ren M, et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res. 2005;11:3535-3542.
4. Kato Y, Yoshimura K, Shin T, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007;13:4538-4546.
5. Hammers HJ, Verheul H, Wilky B, et al. Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer. Clin Oncol. 2008;26: Abstract 16094.
6. Verheul HM, Salumbides B, Van Erp K, et al. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res. 2008;14:3589-3597.